Special Considerations in HIV Management : Episode 1

Video

December 27, 2017

Special Considerations in HIV Management

Throughout this AJMC Peer Exchange^®, a panel of experts in infectious disease and managed care will discuss today’s management of HIV, including the need for individualized care and the role for newer treatment options.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Doctor speaking to a female patient with obesity | Image credit: Studio Romantic - stock.adobe.com

June 18th 2025

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

Laura Joszt, MA

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Plaque psoriasis | Image credit: Milan Lipowski - stock.adobe.com

June 18th 2025

Defining On-Treatment Remission in Plaque Psoriasis

Pearl Steinzor

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Opdivo Qvantig packaging | Image credit: BMS

June 18th 2025

Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?

Mary Caffrey

Atopic dermatitis diagnosis | Image Credit: MP Studio-stock.adobe.com

June 18th 2025

Dupilumab for Atopic Dermatitis May Increase Psoriasis Risk

Maggie L. Shaw

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the importance of monitoring skin reactions during therapy.

Related Content

June 18th 2025

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

Laura Joszt, MA

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 18th 2025

Defining On-Treatment Remission in Plaque Psoriasis

Pearl Steinzor

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 18th 2025

Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?

Mary Caffrey

June 18th 2025

Dupilumab for Atopic Dermatitis May Increase Psoriasis Risk

Maggie L. Shaw

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the importance of monitoring skin reactions during therapy.

Special Considerations in HIV Management

Newsletter